Centessa Pharmaceuticals (CNTA) Cash & Equivalents (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Cash & Equivalents data on file, last reported at $62.4 million in Q1 2026.

• Quarterly Cash & Equivalents fell 40.63% year-over-year to $62.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $62.4 million (down 40.63% YoY) and the FY2025 annual result came in at $61.3 million, down 84.0% from the prior year.
• Cash & Equivalents climbed to $62.4 million in Q1 2026 per CNTA's latest filing, from $61.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $544.5 million in Q1 2022 and bottomed at $44.2 million in Q2 2025.
• The 5-year median for Cash & Equivalents is $145.2 million (2023), against an average of $230.6 million.
• The widest annual swing landed in 2024, when Cash & Equivalents jumped 199.32%; it then sank 87.14% in 2025.
• Tracing CNTA's Cash & Equivalents over 5 years: stood at $393.6 million in 2022, then tumbled by 67.48% to $128.0 million in 2023, then jumped by 199.32% to $383.2 million in 2024, then sank by 84.0% to $61.3 million in 2025, then climbed by 1.85% to $62.4 million in 2026.
• Per Business Quant, the three latest CNTA Cash & Equivalents figures stand at $62.4 million (Q1 2026), $61.3 million (Q4 2025), and $50.8 million (Q3 2025).

Peer Comparison